63
Participants
Start Date
August 30, 2018
Primary Completion Date
June 30, 2025
Study Completion Date
December 31, 2025
Bortezomib and Temozolomide Phase IB
In the Phase IB of the study the following dose escalation of TMZ will be performed: The first cohort of 3 patients will receive 150 mg/m2 of IMP (TMZ) for 5 days q4w. If one patient in this cohort develops a dose limiting toxicity, another cohort of 3 patients will be treated at the same dose level until 2 or more patients in the group of 3-6 develop DLT.
Bortezomib and Temozolomide Phase II
The patientes will be treated with the maximum recommended starting dose of Temozolomide and Bortezomib established in the IB phase of the study
RECRUITING
Haukeland University Hospital, Bergen
RECRUITING
Oslo University Hospital, Oslo
Oslo University Hospital
OTHER
St. Olavs Hospital
OTHER
University Hospital of North Norway
OTHER
University of Bergen
OTHER
University of Bonn
OTHER
University of Oslo
OTHER
Haukeland University Hospital
OTHER